Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature

Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study

(2013) Babafemi Taiwo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting

(2013) José R Arribas et al.   AIDS Research and Therapy

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

(2012) Roger Bedimo et al.   AIDS

A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study

(2012) Ighovwerha Ofotokun et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

(2012) Michael J. Kozal et al.   HIV CLINICAL TRIALS

Renal Toxicity Associated With Antiretroviral Therapy

(2012) Leonardo Calza   HIV CLINICAL TRIALS

A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults

(2012) Dianne Carey et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients

(2012) Anthony Mills et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients

(2012) J. Burgos et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons

(2011) Andy I Choi et al.   AIDS

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

(2011) Babafemi Taiwo et al.   AIDS

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients

(2011) Brian Gazzard et al.   AIDS

Durability and Safety of a Novel Salvage Therapy in R5-Tropic HIV-Infected Patients: Maraviroc, Raltegravir, Etravirine

(2011) Silvia Nozza et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA

(2011) N. Clumeck et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

(2011) Grace A. McComsey et al.   JOURNAL OF INFECTIOUS DISEASES

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

(2010) Amanda Mocroft et al.   AIDS

HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme

(2010) E Florence et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

(2010) Joseph J Eron et al.   LANCET

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

(2009) Mina C Hosseinipour et al.   AIDS

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

(2009) Wouter FW Bierman et al.   AIDS

Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial

(2009) Allison Martin et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of an NRTI-Sparing Dual Regimen of Raltegravir and Ritonavir-Boosted Protease Inhibitor in a Triple Antiretroviral Class-Experienced Population

(2009) C. Allavena et al.   HIV CLINICAL TRIALS

Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels

(2009) Andrew Hill et al.   HIV CLINICAL TRIALS

Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis

(2009) Jose R Arribas et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen

(2009) Todd T Brown et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study

(2009) Signe Westring Worm et al.   JOURNAL OF INFECTIOUS DISEASES

Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

(2008) Sharon A. Riddler et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE